The Longevity Podcast: Alzheimer's and Brain Health Research

Send us Fan Mail

Should doctors check brain health the way they check blood pressure? In this editorial, neurologist Gregory Cooper looks at the Brain Health Vital Signs project, which scores patients on 15 lifestyle risk factors for dementia. He explains how the FINGER, US POINTER, and LatAm-FINGERS trials showed that exercise, diet, mental challenge, social connection, and heart health can protect thinking skills, and why clinics now need practical ways to help patients with memory problems follow that advice.

Source: Cooper G, Is it time to make brain health a vital sign?, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100654 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Even patients chasing new Alzheimer's antibody drugs often skip the lifestyle basics that protect the brain. A Brain Health Vital Signs study of 150 people with early Alzheimer's found fewer than 3% met all 15 consensus recommendations, with the biggest gaps in exercise, mood and stress, blood sugar, blood pressure, and weight. Those pursuing anti-amyloid therapy looked no better than those who were not.

Source: Daffner KR, Riera K, Ghorayeb GR, McFeeley BM, Weizenbaum E, Willment K, Gale SA, Suboptimal adherence to brain health recommendations in patients pursuing anti-amyloid antibody therapy for Alzheimer's disease: Report from the Brain Health Vital Signs project, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100640 (CC BY-NC-ND 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Most brain-healthy diet advice, like the Mediterranean and MIND diets, comes from studies of Western populations. In this editorial, Lei Feng of the National University of Singapore responds to a new review of diet and Alzheimer's risk across East and West. He highlights the Shanghai Cognitive Diet Pattern, which is built around what Chinese adults actually eat, and explains why whole dietary patterns tell us more than single nutrients. He also points to mixed trial results, including the MIND Diet Trial, which didn't beat its control diet, and argues for culturally adapted, personalized nutrition backed by long-term randomized trials.

Source: Lei Feng, Dietary patterns for cognitive health: bridging evidence across east and west, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100663 (CC BY-NC-ND 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Does what you eat shape your risk of Alzheimer's disease, and does the answer change between Eastern and Western diets? This episode digs into a 2026 review in the Journal of Prevention of Alzheimer's Disease that compares dietary patterns across East and West, including the Mediterranean and MIND diets and traditional Asian eating patterns, and what the evidence says about future diet-based prevention strategies for dementia and brain health.

Source: Jiang et al., "Dietary patterns and Alzheimer's disease: East-west perspectives and future intervention strategies," J Prev Alzheimers Dis. 2026. https://doi.org/10.1016/j.tjpad.2026.100636

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

People with atrial fibrillation (AFib), a common irregular heart rhythm, face a higher risk of developing dementia. This study followed 91,795 UK Biobank participants who wore activity trackers. It found that people with AFib who got at least 150 minutes a week of moderate-to-vigorous activity had a lower AFib-related dementia risk. Interestingly, the activity people reported themselves only loosely matched what the trackers measured, and self-reported activity wasn't linked to lower dementia risk. The findings suggest that staying active may help protect brain health in people with AFib, though longer studies are needed to confirm this.

Source: Le Li, Mengtong Xu, Lingmin Wu, et al., Effect of accelerometer-measured physical activity on the association between atrial fibrillation and risk of dementia, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100603 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Your brain’s future might be readable from your cardiovascular risk score right now. We walk through a dense but deeply practical research paper from the Journal of Prevention of Alzheimer’s Disease that links 10-year ASCVD risk to the pace of cognitive decline, without needing a brain scan to spot the warning signs. The big idea is simple: cognitive preservation is not just a neuroscience problem. It is a vascular health problem, and the “plumbing” shows up in numbers you can measure today.

We trace the study’s real-world setting in Project Frontier, following adults in rural West Texas where access to specialty care is harder and unmanaged chronic conditions can quietly compound. Then we unpack how the AHA PREVENT equations build an ASCVD risk score using systolic blood pressure, cholesterol, diabetes status, smoking, and kidney function (eGFR). That score is usually treated as a heart attack and stroke forecast, but here it acts as a proxy for cumulative microvascular stress that also threatens the brain’s smallest vessels.

On the cognition side, we break down the RBANS battery and supporting tests like Trail Making, verbal fluency, and clock drawing. The key pattern is unsettling and specific: higher cardiovascular disease risk aligns with faster drops in attention and delayed memory, while some language and visuospatial skills look more protected in the short window. We also explore why long-term baseline risk matters more than one-off spikes, how “practice effects” reveal neuroplasticity, and why education and income can create cognitive reserve even when vascular damage is present.

If you care about memory, focus, and staying sharp, this is a roadmap to what to monitor and what to change. Subscribe, share this with someone who thinks brain health is only about the brain, and leave a review with your biggest takeaway.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

You know that moment when you open the refrigerator and forget what you came for, or you recognize an actor’s face but their name is gone? Most of us laugh it off, but the fear behind it is real: what if it’s not stress or sleep, but the earliest sign of Alzheimer’s disease?

We break down a landmark 2026 study that asks a surprisingly uncomfortable question: who is the more reliable narrator of your cognitive health, you or the person closest to you? Using the Everyday Cognition (ECog) questionnaire across large longitudinal cohorts, researchers compare self-reports with “study partner” reports from spouses and adult children, then link both to hard biology like amyloid beta and tau. Along the way we explain why quick screening tools like the MMSE can miss subtle declines in planning, language, navigation, and multitasking, and why a single baseline snapshot can be misleading when Alzheimer’s pathology can build silently for years.

The most important twist is about insight. As Alzheimer’s progresses, many people begin to lose accurate self-awareness due to anosognosia, a neurological inability to perceive impairment that is not simple denial. That’s why the partner’s year-over-year observations can become the loudest early alarm, and why a one-year increase in partner-rated ECog can signal sharply higher near-term risk when amyloid is present. We also zoom out to the big implication: what happens to early detection for people who live alone, and could AI, wearables, or smart homes someday act as a “digital study partner”?

If this made you rethink memory concerns and caregiver observations, subscribe, share this with someone supporting an aging loved one, and leave a review with the biggest question you’re still sitting with.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

In the European Union, the Alzheimer's drug donanemab is approved for a narrower group of people with early symptomatic Alzheimer's disease. They must carry no copies or one copy of the APOE ε4 gene variant, and they can't have certain signs of brain bleeding, uncontrolled high blood pressure, or be taking blood thinners. This analysis of the TRAILBLAZER-ALZ 2 trial looked only at participants who would meet those EU criteria. In that group, donanemab slowed disease progression compared with placebo, and the benefit grew over 154 weeks of follow-up. The safety profile was described as manageable, though brain swelling (ARIA-E) and infusion reactions still happened in some patients. It shows how the drug performs in the patients European doctors can actually prescribe it for.

Source: Frank Jessen, Grazia Dell'Agnello, Jennifer A. Zimmer, et al., Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100605 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Alzheimer’s has been treated like a neuron problem for decades, but what if the real lever sits in the brain’s support system, quietly failing long before symptoms show up? We dig into a 2026 Journal of Prevention of Alzheimer’s Disease paper that uses a massive transcriptomic dragnet across multiple human datasets to spotlight one surprising hub: CD44, a receptor best known outside the brain, now showing up as a major signal across vulnerable Alzheimer’s regions.

We walk through why amyloid plaque clearing therapies can slow decline yet still come with modest benefit and serious tradeoffs like ARIA, frequent infusions, and intensive monitoring. Then we follow the evidence trail: region-by-region gene expression analysis, network hub logic, convergent functional genomic ranking, and the clinical “timeline paradox” where CD44 spikes in asymptomatic Alzheimer’s but does not neatly track with later cognitive severity. That pattern pushes us to treat CD44 as an early priming event, not a late-stage scar.

The biggest shift comes from single-nucleus RNA sequencing. CD44 is not coming from dying neurons. It is concentrated in astrocytes, particularly a neurotoxic reactive subpopulation tied to impaired autophagy, the brain’s protein waste recycling system. Using cell-to-cell communication modeling, the paper implicates microglial osteopontin (SPP1) signaling into astrocyte CD44, potentially jamming intracellular transport and stalling autophagic “garbage trucks.” We also cover the Petri-dish validation where CD44 knockdown restores autophagic flux markers and CD44 overexpression makes them worse.

If you care about Alzheimer’s disease research, astrocytes, microglia, autophagy, and next-generation therapeutic targets beyond amyloid, this is the map. Subscribe, share this with a friend who follows neuroscience, and leave a review with your take: should the next wave of trials prioritize restoring brain cleanup over clearing plaques?

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!

Send us Fan Mail

Imagine learning that your brain is on a specific trajectory toward memory loss and you find out from a routine blood draw, not a spinal tap, not a hard-to-access PET scan. That future is arriving fast, and it’s creating a new challenge: we don’t have one “Alzheimer’s blood test” anymore. We have a growing menu of brain biomarkers, each reporting on a different kind of cellular crisis, and the only way to use them well is to match the marker to the underlying biology.

We walk through four of the biggest names in blood-based dementia diagnostics and brain health monitoring: p-tau217, p-tau181, NFL (neurofilament light chain), and GFAP. You’ll learn what each protein normally does, what it means when it shows up in plasma, and how ultrasensitive Simoa technology can measure these signals at almost unimaginable concentrations. Then we dig into a rigorous 2026 study that compares two very different cohorts, a South Korean memory clinic group and the North American ADNI research cohort, to test whether these biomarkers hold up across demographics, education levels, and disease stages.

The headline finding is a true plot twist: amyloid status flips the winners. In amyloid-positive people, p-tau217 emerges as the strongest predictor of cognitive decline, while GFAP can be a dominant signal for brain atrophy in symptomatic patients. In amyloid-negative people, NFL becomes the most reliable indicator of neurodegeneration and overall cognitive worsening, pointing to non-Alzheimer’s causes where general axonal injury is the key story. If you care about early Alzheimer’s detection, precision neurology, or the future of dementia screening, this is the framework to know. Subscribe, share this with someone navigating memory concerns, and leave a review with the biomarker question you want answered next.

This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. 

Never miss an episode—subscribe on your favorite podcast app!